FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3011520450> ?p ?o ?g. }

• W3011520450 abstract "HomeCirculationVol. 141, No. 15The Role of the American Heart Association in the Global COVID-19 Pandemic Free AccessLetterPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessLetterPDF/EPUBThe Role of the American Heart Association in the Global COVID-19 Pandemic Mitchell S.V. Elkind, Robert A. Harrington and Ivor J. Benjamin Mitchell S.V. ElkindMitchell S.V. Elkind Mitchell S.V. Elkind, MD, Columbia University, Neurological Institute of New York, 710 W 168th St, New York, NY 10032. Email E-mail Address: [email protected] https://orcid.org/0000-0003-2562-1156 Columbia University, New York, NY (M.S.V.E.). Search for more papers by this author , Robert A. HarringtonRobert A. Harrington Stanford University, Palo Alto, CA (R.A.H.). Search for more papers by this author and Ivor J. BenjaminIvor J. Benjamin Medical College of Wisconsin, Milwaukee (I.J.B.). Search for more papers by this author Originally published17 Mar 2020https://doi.org/10.1161/CIRCULATIONAHA.120.046749Circulation. 2020;141:e743–e745Other version(s) of this articleYou are viewing the most recent version of this article. Previous versions: March 17, 2020: Ahead of Print As the United States and the world confront the novel coronavirus (COVID-19) pandemic, the American Heart Association (AHA) and its thousands of science volunteers have an important role to play to help stop the spread.That may seem counterintuitive to some, considering that COVID-19 is an infectious disease and the AHA has spent the last nearly 100 years focused on noncommunicable diseases such as cardiovascular diseases (CVDs), stroke, and other vascular disorders. However, COVID-19 is very much a concern of the AHA because patients with underlying cardiovascular conditions appear to face a greater risk of complications. In addition, as an organization dedicated to overall health and well-being, we are very concerned about significant domestic and global health problems.Contagious Infections and CVDEven before the first outbreak of COVID-19, the AHA and its professional members were aware of evidence suggesting that acute coronary events and strokes could be triggered by common infections.1,2 Respiratory and urinary tract infections, among others, have been associated with a short-term increase in the risk of myocardial infarction and ischemic stroke.3 Influenza in particular is associated with increased risk, and some clinical trials provide additional evidence that the influenza vaccination decreases cardiovascular risk.1 Since 2006, the AHA and the American College of Cardiology have recommended that patients with CVD receive the influenza vaccination to prevent flu-related respiratory disease and other complications, including cardiovascular events.3 This approach represents the first instance of routine use of anti-infective strategies to reduce CVD. Mechanisms for the increase in risk with influenza remain unclear but may reflect greater cardiovascular stress in the setting of infection, reduced oxygenation in the setting of lung disease, or systemic inflammation with consequent thrombosis or intraplaque disruption predisposing to rupture.Although much remains unknown about COVID-19, it is reasonable to assume that increased risk of cardiovascular events after infection is possible. In China, CVD and hypertension were associated with an increased COVID-19 case fatality rate.4 Among patients who died of COVID-19, substantial cardiac damage was observed.5 Furthermore, it appears that elderly people with coronary heart disease or hypertension are more likely to be infected and to develop more severe symptoms. Surveillance for cardiovascular events after COVID-19 seems very warranted, and this could be an area for future investigation.Preparing to Mitigate SpreadIt is important to understand that we are in a mitigation phase for this pandemic. Mitigation strategies are nonpharmaceutical interventions to help slow the transmission of the virus in communities before drugs for treatment or a vaccine becomes available from the Centers for Disease Control and Prevention. However, although prevention and avoidance are important, preparedness in clinical settings, particularly acute care hospitals, is now crucial to ensure the ability to care for more COVID-19 cases. The number of reported cases is increasing rapidly. As of March 16, the Centers for Disease Control and Prevention had confirmed 1629 US cases and 41 deaths in the United States.6 More than 125 000 people worldwide have COVID-19, and >4600 people have died, mostly in China.7During this mitigation phase, it is crucial that public health agencies, hospitals, healthcare systems, and others focused on the public’s health learn from missteps early on and subsequent successful mitigation in China. We need to anticipate what is to come. It is increasingly likely that critical care physicians and cardiologists will be called on to assist in the care of persons with COVID-19 who have underlying CVD or who develop cardiac complications. Many of the AHA clinical care volunteers will be on the front lines.AHA’s role also will be crucial in the dissemination of science-based information about COVID-19 for patients, caregivers, and their families from a trusted source. We will continue to track developments by following reports from the Centers for Disease Control and Prevention and the World Health Organization and provide science-based, common-sense updates and guidance on our website, in social media, and in syndicated news stories that reach millions of people. We will continue to share best practices on how people can protect themselves from COVID-19; steps that individuals with CVD, stroke, and other vascular conditions should take; and measures people should take if they develop COVID-19. At times of crisis especially, people need understandable and actionable information from credible sources.The AHA’s Expanded MissionOur mission is to be a relentless force for a world of longer, healthier lives, and our 2030 Impact Goals aim to achieve a 2-year increase in healthy life expectancy in the United States and 3 years globally.8 Cardiovascular health and brain health are integral to extending healthy life expectancy. Furthermore, optimized mental health extends healthy life expectancy.Social determinants of health, including education, income, geographic location, and access to care, are essential to cardiovascular and brain health as well as overall health and well-being. In the face of this crisis, we are likely to witness the dramatic ways in which social determinants affect outcomes to severe, acute illness. Countries and regions with fewer resources are likely to face higher mortality and morbidity than areas with greater access to care, particularly as increasing numbers of cases overwhelm local healthcare systems, as is already being seen in parts of Italy. Ultimately, the case fatality rate of COVID-19 is likely to be less a property of the virus or of individuals infected and more a function of each healthcare system affected.Once the AHA began to tackle social determinants and to work to extend healthy life expectancy, it became imperative to ensure that the organization address aspects of health and well-being that may have traditionally fallen outside of cardiovascular research and practice. Areas such as brain health, air quality, health insurance reform, rural health, and more are now part of our mission.9,10 There is no way to draw a sharp demarcation between cardiovascular health and general health and well-being.Health equity is incorporated into all AHA activities, and health equity is never challenged more than in the face of crisis. We have already begun to see threats to individuals related to this pandemic: disinformation, disparities in access to health care, xenophobia, racism, and prejudice. Each has the potential to undermine the public health response. Trust is essential to a rational approach to this crisis, and the AHA is one of the most trusted brands in the world.Positioned to HelpAs a catalyst for change and a convener, the AHA will continue to work with our many partners to educate and activate the public and to partner with other organizations to take action. Our work touches on population-level, clinical, translational, and basic science research. The AHA maintains a large network of cardiologists, neurologists, and other specialists and disciplines—more than 30 000 committed individuals with clinical and scientific expertise. We have partnerships with US and international governments, other international agencies, large health systems, industry, and others with the capacity to assist.This outbreak underscores the need to modernize our public health surveillance infrastructure with state-of-the-art, interoperable data systems, security to protect data, a workforce prepared for the information age, and partnership and innovation between the public and private sectors. The AHA will support efforts to make this modernization happen at the local, state, federal, and global levels. This will ensure a robust public health infrastructure that can target focused and effective local, state, and national action to improve population health and well-being.We call on our AHA members, clinical volunteers, and others to aid these efforts; to heed the guidance of the Centers for Disease Control and Prevention, World Health Organization, and state and local health departments; and to share best practices.Together with the public health and healthcare community, we are working toward the same goals: preventing COVID-19 to the fullest extent possible, ensuring that people with COVID-19 can be identified and receive care, developing treatments and a vaccine, ultimately stopping COVID-19, and laying the groundwork for the robust public health and healthcare system of the future.AcknowledgmentsThe authors thank John McFarland for his assistance in preparing the manuscript.DisclosuresDr Elkind receives ancillary funding from Roche and study drug in kind from the BMS-Pfizer Alliance for Eliquis for a National Institutes of Health–funded trial of stroke prevention; he also receives royalties from UpToDate for chapters related to stroke. He is also an officer of the American Heart Association (unpaid); he also served on the Stanford Healthcare Board of Directors from 2016-2018 (unpaid). Dr Benjamin reports no conflicts.Footnoteshttps://www.ahajournals.org/journal/circMitchell S.V. Elkind, MD, Columbia University, Neurological Institute of New York, 710 W 168th St, New York, NY 10032. Email mse13@columbia.eduReferences1. Smeeth L, Thomas SL, Hall AJ, Hubbard R, Farrington P, Vallance P. Risk of myocardial infarction and stroke after acute infection or vaccination.N Engl J Med. 2004; 351:2611–2618. doi: 10.1056/NEJMoa041747CrossrefMedlineGoogle Scholar2. Elkind MSV. Why now? Moving from stroke risk factors to stroke triggers.Curr Opin Neurol. 2007; 20:51–57. doi: 10.1097/WCO.0b013e328012da75CrossrefMedlineGoogle Scholar3. Davis MM, Taubert K, Benin AL, Brown DW, Mensah GA, Baddour LM, Dunbar S, Krumholz HM; American Heart Association; American College of Cardiology. Influenza vaccination as secondary prevention for cardiovascular disease: a science advisory from the American Heart Association/American College of Cardiology.Circulation. 2006; 114:1549–1553. doi: 10.1161/CIRCULATIONAHA.106.178242LinkGoogle Scholar4. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention [published online February 24, 2020].JAMA. doi: 10.1001/jama.2020.2648. https://jamanetwork.com/journals/jama/fullarticle/2762130.Google Scholar5. Zheng Y-Y, Ma Y-T, Zhang J-Y, Xie X. COVID-19 and the cardiovascular system [published online March 5, 2020].Nat Rev Cardiol. doi: 10.1038/s41569-020-0360-5. https://www.nature.com/articles/s41569-020-0360-5.Google Scholar6. Centers for Disease Control and Prevention. Coronavirus disease 2019 (COVID-19) in the U.S.https://www.cdc.gov/coronavirus/2019-ncov/cases-in-us.html. Accessed March 16, 2020.Google Scholar7. World Health Organization. Coronavirus disease (COVID-2019) situation reports.https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports/. Accessed March 16, 2020.Google Scholar8. Angell SY, McConnell MV, Anderson CAM, Bibbins-Domingo K, Boyle DS, Capewell S, Ezzati M, de Ferranti S, Gaskin DJ, Goetzel RZ, et al. The American Heart Association 2030 Impact Goal: a presidential advisory from the American Heart Association.Circulation. 2020; 141:e120–e138. doi: 10.1161/CIR.0000000000000758LinkGoogle Scholar9. Warner JJ, Benjamin IJ, Churchwell K, Firestone G, Gardner TJ, Johnson JC, Ng-Osorio J, Rodriguez CJ, Todman L, Yaffe K, et al. Advancing healthcare reform: the American Heart Association’s 2020 statement of principles for adequate, accessible, and affordable health care: a presidential advisory from the American Heart Association.Circulation. 2020; 141:e601–e614. doi: 10.1161/CIR.0000000000000759LinkGoogle Scholar10. Harrington RA, Califf RM, Balamurugan A, Brown N, Benjamin RM, Braund WE, Hipp J, Konig M, Sanchez E, Joynt Maddox KE. Call to action: rural health: a presidential advisory from the American Heart Association and American Stroke Association.Circulation. 2020; 141:e615–e644. doi: 10.1161/CIR.0000000000000753LinkGoogle Scholar eLetters(0)eLetters should relate to an article recently published in the journal and are not a forum for providing unpublished data. Comments are reviewed for appropriate use of tone and language. Comments are not peer-reviewed. Acceptable comments are posted to the journal website only. Comments are not published in an issue and are not indexed in PubMed. Comments should be no longer than 500 words and will only be posted online. References are limited to 10. Authors of the article cited in the comment will be invited to reply, as appropriate.Comments and feedback on AHA/ASA Scientific Statements and Guidelines should be directed to the AHA/ASA Manuscript Oversight Committee via its Correspondence page.Sign In to Submit a Response to This Article Previous Back to top Next FiguresReferencesRelatedDetailsCited By Xue H, Zhang J, Sagae K, Nishimine B and Fukuoka Y (2022) Analyzing Public Conversations About Heart Disease and Heart Health on Facebook From 2016 to 2021: Retrospective Observational Study Applying Latent Dirichlet Allocation Topic Modeling, JMIR Cardio, 10.2196/40764, 6:2, (e40764) Zahran I, Megdadi Y and Albloush A (2022) The impact of COVID-19 risk perceptions on intentions to consume energy beverages: The mediation role of a healthy lifestyle and sustainable consumption, Innovative Marketing, 10.21511/im.18(4).2022.10, 18:4, (110-122), Online publication date: 22-Nov-2022. Van Steenburg E, Anaza N, Ashhar A, Barrios A, Deutsch A, Gardner M, Priya P, Roy A, Sivaraman A and Taylor K (2022) The new world of philanthropy: How changing financial behavior, public policies, and COVID ‐19 affect nonprofit fundraising and marketing , Journal of Consumer Affairs, 10.1111/joca.12461, 56:3, (1079-1105), Online publication date: 1-Sep-2022. Alameri F, Aldaheri N, Almesmari S, Basaloum M, Albeshr N, Simsekler M, Ugwuoke N, Dalkilinc M, Al Qubaisi M, Campos L, Almahmeed W, Alefishat E, Al Tunaiji H and Baltatu O (2022) Burnout and Cardiovascular Risk in Healthcare Professionals During the COVID-19 Pandemic, Frontiers in Psychiatry, 10.3389/fpsyt.2022.867233, 13 Venturelli A, Vitolo M, Albini A and Boriani G (2021) How did COVID-19 affect medical and cardiology journals? A pandemic in literature, Journal of Cardiovascular Medicine, 10.2459/JCM.0000000000001245, 22:11, (840-847), Online publication date: 1-Nov-2021. Bychkova L, Shmaevskii P, Rodoman , Mukovnikova E, Tsigura D and Robyshev V (2021) COVID-associated coagulopathy and its consequences, Hirurg (Surgeon), 10.33920/med-15-2104-05:7-8, (56-71), Online publication date: 10-Jul-2021. Ferrero P, Chessa M, Piazza I, Bonino C, Ferrari I, Giamberti A, Ciuffreda M and Dimopoulos K (2021) COVID-19 in adults with congenital heart disease: early morbidity and mortality in two northern Italian specialist centers, Italian Journal of Medicine, 10.4081/itjm.2021.1397, 15:1 Mizuno A, Matsumoto C, Yoneoka D, Kishi T, Ishida M, Sanada S, Fukuda M, Saito Y, Yamauchi-Takihara K, Tsutsui H, Fukuda K, Komuro I and Node K (2021) Cardiology Department Practices in the First Wave of the Coronavirus Disease Pandemic ― A Nationwide Survey in Japan by the Japanese Circulation Society―, Circulation Reports, 10.1253/circrep.CR-21-0002, 3:3, (137-141), Online publication date: 10-Mar-2021. Wang M, Hu C, Zhao Q, Feng R, Wang Q, Cai H, Guo Z, Xu K, Luo W, Guo C, Zhang S, Chen C, Zhu C, Wang H, Chen Y, Ma L, Zhan P, Cao J, Huang S, Yang M, Fang Y, Zhu S and Yang Y (2021) Acute psychological impact on COVID-19 patients in Hubei: a multicenter observational study, Translational Psychiatry, 10.1038/s41398-021-01259-0, 11:1 de Oliveira R, de Souza Aguiar P, de Paula R, Simões C, Almeida L, Barceló A and Galil A (2020) Stroke in patients infected by the novel coronavirus and its causal mechanisms: A narrative review, Journal of the American College of Emergency Physicians Open, 10.1002/emp2.12332, 2:1, Online publication date: 1-Feb-2021. Wang Z, Pu Q, Huang C and Wu M (2021) Crosstalk Between Lung and Extrapulmonary Organs in Infection and Inflammation Lung Inflammation in Health and Disease, Volume I, 10.1007/978-3-030-63046-1_18, (333-350), . Wang D, Gee G, Bahiru E, Yang E and Hsu J (2020) Asian-Americans and Pacific Islanders in COVID-19: Emerging Disparities Amid Discrimination, Journal of General Internal Medicine, 10.1007/s11606-020-06264-5, 35:12, (3685-3688), Online publication date: 1-Dec-2020. Keihanian F and Bigdelu L (2020) Cardiovascular Considerations in COVID19: A Comprehensive Review, Therapeutics and Clinical Risk Management, 10.2147/TCRM.S264377, Volume 16, (1089-1097) Akram W, Menezes G, Abbas N, Ahmad W and Ahmed A (2020) Treatment of Multi-Drug Resistant Gram-Negative Bacterial Pathogenic Infections, Journal of Pure and Applied Microbiology, 10.22207/JPAM.14.3.02, 14:3, (1639-1647), Online publication date: 30-Sep-2020. Arumugam V, Thangavelu S, Fathah Z, Ravindran P, Sanjeev A, Babu S, Meyyazhagan A, Yatoo M, Sharun K, Tiwari R, Pandey M, Sah R, Chandra R and Dhama K (2020) COVID-19 and the World with Co-Morbidities of Heart Disease, Hypertension and Diabetes, Journal of Pure and Applied Microbiology, 10.22207/JPAM.14.3.01, 14:3, (1623-1638), Online publication date: 30-Sep-2020. Skali H, Murthy V, Al-Mallah M, Bateman T, Beanlands R, Better N, Calnon D, Dilsizian V, Gimelli A, Pagnanelli R, Polk D, Soman P, Thompson R, Einstein A and Dorbala S (2020) Guidance and Best Practices for Nuclear Cardiology Laboratories During the COVID-19 Pandemic, Circulation: Cardiovascular Imaging, 13:9, Online publication date: 1-Sep-2020. Martins-Filho P, Barreto-Filho J and Santos V (2020)(2020)(2020)(2020) Biomarcadores de Lesão Miocárdica e Complicações Cardíacas Associadas à Mortalidade em Pacientes com COVID-19, Arquivos Brasileiros de Cardiologia, 10.36660/abc.20200372, 115:2, (273-277), Online publication date: 19-Aug-2020., Online publication date: 19-Aug-2020., Online publication date: 1-Aug-2020., Online publication date: 1-Aug-2020. Co C, Yu J, Laxamana L and David-Ona D (2020) Intravenous Thrombolysis for Stroke in a COVID-19 Positive Filipino Patient, a Case Report, Journal of Clinical Neuroscience, 10.1016/j.jocn.2020.05.006, 77, (234-236), Online publication date: 1-Jul-2020. Dzhioeva O and Drapkina O (2020) Heart ultrasound in COVID-19, Arterial’naya Gipertenziya (Arterial Hypertension), 10.18705/1607-419X-2020-26-3-270-276, 26:3, (270-276) Skulstad H, Cosyns B, Popescu B, Galderisi M, Salvo G, Donal E, Petersen S, Gimelli A, Haugaa K, Muraru D, Almeida A, Schulz-Menger J, Dweck M, Pontone G, Sade L, Gerber B, Maurovich-Horvat P, Bharucha T, Cameli M, Magne J, Westwood M, Maurer G and Edvardsen T (2020) COVID-19 pandemic and cardiac imaging: EACVI recommendations on precautions, indications, prioritization, and protection for patients and healthcare personnel, European Heart Journal - Cardiovascular Imaging, 10.1093/ehjci/jeaa072, 21:6, (592-598), Online publication date: 1-Jun-2020. Skali H, Murthy V, Al-Mallah M, Bateman T, Beanlands R, Better N, Calnon D, Dilsizian V, Gimelli A, Pagnanelli R, Polk D, Soman P, Thompson R, Einstein A and Dorbala S (2020) Guidance and best practices for nuclear cardiology laboratories during the coronavirus disease 2019 (COVID-19) pandemic: An Information Statement from ASNC and SNMMI, Journal of Nuclear Cardiology, 10.1007/s12350-020-02123-2, 27:3, (1022-1029), Online publication date: 1-Jun-2020. López-Fernández T (2020) Cardiac Imaging in Oncology Patients in Europe: a Model for Advancement of CV Safety and Development of Comprehensive CV Care, Journal of Cardiovascular Translational Research, 10.1007/s12265-020-10028-1, 13:3, (490-494), Online publication date: 1-Jun-2020. Ferrari F (2020)(2020) COVID-19: Dados Atualizados e sua Relação Com o Sistema Cardiovascular, Arquivos Brasileiros de Cardiologia, 10.36660/abc.20200215, Online publication date: 8-May-2020., Online publication date: 8-May-2020. Harrington R and Warner J (2020) Protecting Our Front Line, Circulation: Cardiovascular Interventions, 13:5, Online publication date: 1-May-2020. Shlyakho E, Konradi A, Arutyunov G, Arutyunov A, Bautin A, Boytsov S, Villevalde S, Grigoryeva N, Duplyakov D, Zvartau N, Koziolova N, Lebedev D, Malchikova S, Medvedeva E, Mikhailov E, Moiseeva O, Orlova Y, Pavlova T, Pevsner D, Petrova M, Rebrov A, Sitnikova M, Solovyova A, Tarlovskaya E, Trukshina M, Fedotov P, Fomin I, Khripun A, Chesnikova A, Shaposhnik I, Yavelov I and Yakovlev A (2020) Guidelines for the diagnosis and treatment of circulatory diseases in the context of the COVID-19 pandemic, Russian Journal of Cardiology, 10.15829/1560-4071-2020-3-3801, 25:3, (3801) Drapkina O and Dzhioeva O (2020) Algorithms for organizing and conducting ultrasound examinations of the heart and lungs during a epidemic COVID-19, Profilakticheskaya meditsina, 10.17116/profmed20202307147, 23:7, (47), . April 14, 2020Vol 141, Issue 15 Advertisement Article InformationMetrics © 2020 American Heart Association, Inc.https://doi.org/10.1161/CIRCULATIONAHA.120.046749PMID: 32181680 Originally publishedMarch 17, 2020 Keywordshypertensionlife expectancycoronavirus infectionspandemicsepidemiologyheart failuresocial determinants of diseasePDF download Advertisement" @default.
• W3011520450 created "2020-03-23" @default.
• W3011520450 creator A5004573225 @default.
• W3011520450 creator A5021756508 @default.
• W3011520450 creator A5060370891 @default.
• W3011520450 date "2020-04-14" @default.
• W3011520450 modified "2023-10-10" @default.
• W3011520450 title "The Role of the American Heart Association in the Global COVID-19 Pandemic" @default.
• W3011520450 cites W2011140183 @default.
• W3011520450 cites W2144873061 @default.
• W3011520450 cites W2746749900 @default.
• W3011520450 cites W3004406948 @default.
• W3011520450 cites W3005316207 @default.
• W3011520450 cites W3006148615 @default.
• W3011520450 doi "https://doi.org/10.1161/circulationaha.120.046749" @default.
• W3011520450 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7172571" @default.
• W3011520450 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32181680" @default.
• W3011520450 hasPublicationYear "2020" @default.
• W3011520450 type Work @default.
• W3011520450 sameAs 3011520450 @default.
• W3011520450 citedByCount "30" @default.
• W3011520450 countsByYear W30115204502020 @default.
• W3011520450 countsByYear W30115204502021 @default.
• W3011520450 countsByYear W30115204502022 @default.
• W3011520450 crossrefType "journal-article" @default.
• W3011520450 hasAuthorship W3011520450A5004573225 @default.
• W3011520450 hasAuthorship W3011520450A5021756508 @default.
• W3011520450 hasAuthorship W3011520450A5060370891 @default.
• W3011520450 hasBestOaLocation W30115204501 @default.
• W3011520450 hasConcept C111472728 @default.
• W3011520450 hasConcept C116675565 @default.
• W3011520450 hasConcept C126322002 @default.
• W3011520450 hasConcept C138885662 @default.
• W3011520450 hasConcept C142853389 @default.
• W3011520450 hasConcept C159047783 @default.
• W3011520450 hasConcept C164705383 @default.
• W3011520450 hasConcept C2778137277 @default.
• W3011520450 hasConcept C2779134260 @default.
• W3011520450 hasConcept C2909376813 @default.
• W3011520450 hasConcept C3006700255 @default.
• W3011520450 hasConcept C3007834351 @default.
• W3011520450 hasConcept C3008058167 @default.
• W3011520450 hasConcept C524204448 @default.
• W3011520450 hasConcept C71924100 @default.
• W3011520450 hasConcept C89623803 @default.
• W3011520450 hasConceptScore W3011520450C111472728 @default.
• W3011520450 hasConceptScore W3011520450C116675565 @default.
• W3011520450 hasConceptScore W3011520450C126322002 @default.
• W3011520450 hasConceptScore W3011520450C138885662 @default.
• W3011520450 hasConceptScore W3011520450C142853389 @default.
• W3011520450 hasConceptScore W3011520450C159047783 @default.
• W3011520450 hasConceptScore W3011520450C164705383 @default.
• W3011520450 hasConceptScore W3011520450C2778137277 @default.
• W3011520450 hasConceptScore W3011520450C2779134260 @default.
• W3011520450 hasConceptScore W3011520450C2909376813 @default.
• W3011520450 hasConceptScore W3011520450C3006700255 @default.
• W3011520450 hasConceptScore W3011520450C3007834351 @default.
• W3011520450 hasConceptScore W3011520450C3008058167 @default.
• W3011520450 hasConceptScore W3011520450C524204448 @default.
• W3011520450 hasConceptScore W3011520450C71924100 @default.
• W3011520450 hasConceptScore W3011520450C89623803 @default.
• W3011520450 hasIssue "15" @default.
• W3011520450 hasLocation W30115204501 @default.
• W3011520450 hasLocation W30115204502 @default.
• W3011520450 hasLocation W30115204503 @default.
• W3011520450 hasOpenAccess W3011520450 @default.
• W3011520450 hasPrimaryLocation W30115204501 @default.
• W3011520450 hasRelatedWork W3034139802 @default.
• W3011520450 hasRelatedWork W3036899716 @default.
• W3011520450 hasRelatedWork W3042427510 @default.
• W3011520450 hasRelatedWork W3045573749 @default.
• W3011520450 hasRelatedWork W3127941442 @default.
• W3011520450 hasRelatedWork W3128585611 @default.
• W3011520450 hasRelatedWork W3199363150 @default.
• W3011520450 hasRelatedWork W4280491013 @default.
• W3011520450 hasRelatedWork W4310828482 @default.
• W3011520450 hasRelatedWork W3107152225 @default.
• W3011520450 hasVolume "141" @default.
• W3011520450 isParatext "false" @default.
• W3011520450 isRetracted "false" @default.
• W3011520450 magId "3011520450" @default.
• W3011520450 workType "article" @default.